Pharmaxis Aridol Approved for Sale in Switzerland
20 Ottobre 2008 - 1:25AM
PR Newswire (US)
SYDNEY, Australia, Oct. 19 /Xinhua-PRNewswire-FirstCall/ --
Pharmaceutical company Pharmaxis (ASX:PXS)(NASDAQ:PXSL) today
announced that it had received approval to market Aridol from the
Swiss therapeutic regulatory agency Swissmedic. Aridol is indicated
for measuring airway hyperresponsiveness and within Europe is now
approved in 13 countries - Denmark, Finland, France, Germany,
Greece, Ireland, The Netherlands, Norway, Portugal, Spain, Sweden,
Switzerland and the United Kingdom. "Swiss physicians have been
some of the earliest adopters of Aridol, pioneering early clinical
trials, so I am delighted to have the product approved there" said
Pharmaxis CEO Dr Alan Robertson. "This level of innovation has
attracted the attention of two multinational Pharma companies who
are currently funding studies in Switzerland that utilize Aridol to
diagnose asthma and COPD patients who will respond to inhaled
corticosteroids". Aridol will be distributed in Switzerland by
Trimedal, a specialist respiratory and allergy pharmaceutical
company based in Zurich, Switzerland. It has an extensive network
of contacts with pulmonary specialists, allergists and respiratory
laboratories that will be critical for the market success of
Aridol. Pricing for Aridol in Switzerland is included under an
existing reimbursement code so marketing may commence immediately.
A simple-to-use airways inflammation test, Aridol is a dry powder
administered to patients' lungs via a small hand-held inhaler.
Doctors can use the results of this test to identify airway
hyperresponsiveness - a hallmark of asthma. Medications can be
adjusted according to the severity of the disease. Forward-Looking
Statements The statements contained in this media release that are
not purely historical are forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements in this media release include
statements regarding our expectations, beliefs, hopes, goals,
intentions, initiatives or strategies, including statements
regarding the potential for Aridol and/or Bronchitol. All
forward-looking statements included in this media release are based
upon information available to us as of the date hereof, and we
assume no obligation to update any such forward-looking statement
as a result of new information, future events or otherwise. We can
not guarantee that any product candidate will receive FDA or other
regulatory approval or that we will seek any such approval. Factors
that could cause or contribute to such differences include, but are
not limited to, factors discussed in the "Risk Factors and Other
Uncertainties" section of our Form 20-F lodged with the U.S.
Securities and Exchange Commission. For more information, please
contact: Alan Robertson, Chief Executive Officer Tel:
+61-2-9454-7200 Email: RELEASED THROUGH: Australia: Felicity
Moffatt, Tel: +61-418-677-701 Email: United States: Brandon Lewis,
Trout Group, Tel: +1-646-378-2915 Email: DATASOURCE: Pharmaxis Ltd
CONTACT: Alan Robertson, Chief Executive Officer, +61-2-9454-7200,
or ; Or RELEASED THROUGH: Australia: Felicity Moffatt,
+61-418-677-701, or ; Or United States: Brandon Lewis of Trout
Group, +1-646-378-2915, or
Copyright
Grafico Azioni Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ:PXSL)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ:PXSL)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ): 0 articoli recenti
Più Pharmaxis Limited - Sponsored Adr (Australia) (MM) Articoli Notizie